和鉑醫藥-B(2142.HK)盤中拉昇漲超12% 向莫德納提供研究平台
格隆匯11月14日丨和鉑醫藥-B(2142.HK)盤中拉昇漲超12%報1.46港元。消息面上,11月11日,和鉑醫藥宣佈其全資子公司諾納生物與全球領先的mRNA及疫苗研發公司莫德納(moderna)簽訂授權及合作協議,根據協議,莫德納將獲得一組由HCAb平台開發的針對多個靶點序列的獨家可再授權許可,用於基因療法的研發,並全面負責其開發、生產、監管及商業化相關的所有工作。諾納生物將一次性獲得600萬美元預付款、最高約5億美元里程碑付款及相關分級特許使用權費。此外,莫德納還將有權選擇獲得額外靶點序列的獨家可再授權許可,諾納生物將獲得相應的預付款、里程碑付款以及分級特許權使用費。另外,和鉑醫藥同時宣佈,促成公司與AZ及moderna等多項合作的原首席戰略官徐偉豪先生已獲委任為首席財務官及首席商務官,自11月11日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.